HitGen UPPTHERA Enter Drug Discovery Research Pact To Identify Small Molecule Hits Against Previous Known-to-be Undruggable Targets And Novel E3 Ligas

HitGen UPPTHERA Enter Drug Discovery Research Pact To Identify Small Molecule Hits Against Previous Known-to-be Undruggable Targets And Novel E3 Ligas

By, Admin 3 March 2021

HitGen, a rapidly developing biotech company, announced that it has entered into drug discovery research collaboration with UPPTHERA, a pharmaceutical venture company, to identify small molecule Hits against previous known-to-be undruggable targets and novel E3 ligase.HitGen will apply its platform technology, based on the design, synthesis and screening of DNA-encoded libraries (DEL) to discover compounds that bind to certain targets. The identified compounds will be exclusively licensed to UPPTHERA for further development. Under the terms of the agreement, HitGen will receive an undisclosed upfront payment, success fee, license/milestone fee from UPPTHERA.“We are delighted to enter this collaboration with UPPTHERA, an emerging pharmaceutical venture company aiming for new drug development based on targeted protein degradation (TPD) technology. We look forward to working closely with UPPTHERA’s research teams to deliver novel small molecules to their programs, ” said Dr. Jin Li, chairman of the board and chief executive officer of HitGen.“HitGen’s DEL screening platform offers tremendous potential to identify a small molecule binder to UPPTHERA’s targets of interest”, said Dr. Siwoo Choi, chief executive officer of UPPTHERA. “Our alliance enables us to discover and develop pipeline of novel therapeutics for diseases which traditional drugs have failed in the past.”

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!